Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLC-391 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- SignalChem Lifesciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SLC-391 + pembrolizumab is a combination therapy being investigated for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). SLC-391 is a selective AXL inhibitor that disrupts cell division, inhibits tumor growth, and causes cancer cells to die. AXL, a member of the TAM family protein tyrosine kinases (Tyro3, AXL and Mer), plays a key role in cell survival, angiogenesis, metastasis and therapeutic resistance. Pembrolizumab (KEYTRUDA) is an anti-PD-1 therapy that works as an immune checkpoint inhibitor. By inhibiting AXL signaling, SLC-391 has the potential to enhance the anti-tumor immune response and sensitize cancer cells to immune checkpoint inhibitors like pembrolizumab.
- Brand names
- SLC-391 + KEYTRUDA
02
Targets
AXL (AXL receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SLC-391 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC-391 + pembrolizumab.